EN DE
Watch LivaNova PLC for free: we tell you when fair value or trend changes.
Data-driven stock valuation

LivaNova PLC (LIVN) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of LivaNova PLC stock $72.21, price $89.99, that is 19.8% below the price, quality 53 out of 100. Rating: overvalued. Calculated from audited financials with 13 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Home United Kingdom · ISIN GB00BYMT0J19

LP LivaNova PLC logo Some data Nov 5, 2026

LivaNova PLC

LIVN · US
Solid, but expensive

Our calculation puts a fair price 20% below what the stock costs today.

Solidly profitable · 13.0% net margin (TTM)
Low debt
Generates free cash flow
Positive coverage
Quality 53/100
Mixed Growth (revenue 5y +8.2 %/yr in USD)
Mixed vs. peers (6/14)
Moderate moat 45/100 · thin data
Insiders sold $1.0M (6M)
Some data
Profit last quarter 78% below a year ago.
Fair value $72.21 · Overvalued (−19.8%)
Watch LivaNova PLC for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$94.19 $33.85 Fair Value $72.21 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.

How to read this chart

60‑month range $33.85 – $94.19 · fair‑value band $42.84 – $110.18 · the $89.99 price screens above the $72.21 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 5, 2026.

Follow LivaNova in your weekly email

Every Wednesday you see whether LivaNova is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally.

Show moreShow less

The company operates in two segments, Cardiopulmonary and Neuromodulation.

The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, and other related accessories, as well as services related products.

The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and difficult-to-treat depression.

This segment also includes the development and clinical testing of LivaNova's aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, and other healthcare professionals, hospitals, and other medical institutions and healthcare providers.

The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

Stock analysis

LivaNova PLC (LIVN) currently trades at $89.99, while our model-based Fair Value estimate is $72.21, 20% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of $80.71 per share, and 2 of the 13 models we run sit above the $89.99 price.

Bear case: the Earnings-Based group reads lowest at $25.79, and 11 of the 13 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $42.84 (bear) to $110.18 (bull), the price of $89.99 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

LivaNova PLC reported revenue of $1.4B in FY2025 versus $1.0B in FY2021, a compound +7.6%/yr. Reported net income was −$243M in FY2025.

Key figures

Market cap $5.1B Mid · P/E ratio 25.8 · P/S ratio 3.36 · EPS (TTM) $3.49 · Net margin 13.0% · Return on equity 15.5% · Return on assets (EBIT) 1.3% (5-year average) · Operating margin 7.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 45 out of 100 (low confidence).

What moves the price

The share trades about 4% below its 52-week high and 82% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −20%, LIVN screens richer than that median.

Fair Value models

Bear $42.84 Fair Value $72.21 Bull $110.18
Price $89.99 · Downside -19.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($2.98 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $57.37 $100.25 $199.68 76
Growth DCF $55.92 $103.54 $174.93 76
5Y EBITDA Exit $42.84 $72.21 $110.18 74
All 13 models by family
DCF Models
FCF DCF $57.37 $100.25 $199.68 76
5Y Revenue Exit $36.51 $58.25 $87.98 72
5Y EBITDA Exit $42.84 $72.21 $110.18 74
10Y Revenue Exit $42.28 $66.03 $103.62 66
10Y EBITDA Exit $47.25 $76.41 $122.99 67
Earnings-Based
EPV $23.01 $25.79 $28.20 74
Multiples
EV/EBIT $32.91 $42.89 $52.88 66
EV/EBITDA $35.65 $46.55 $57.45 67
EV/Revenue $24.33 $33.49 $42.66 54
Asset-Based
NCAV (Graham) $1.61 $2.16 $3.23 54
Growth DCF
Growth DCF $55.92 $103.54 $174.93 76
Rev-Margin DCF $36.51 $57.88 $87.49 72
Economic Profit
ROIC Compounder $23.80 $31.20 $37.89 72

Open the full fair value analysis →

Quality Score breakdown

Overall quality 53/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 20
How much profit the company makes from its sales and capital
Quality Growth 30
Are margins and returns getting better?
Cashflow 60
Do the profits arrive as real cash?
Financial strength 66
Debt, balance sheet and risk of trouble
Investment 86
Does it invest with discipline instead of growing at any price?
Low Volatility 57
How calm the share price moves, does not count
Price momentum 80
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 95
Distance to the 52-week high, does not count
New shares 59
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 3 officers or directors sold shares worth $1.0M and none bought.

  • SaleFrancesco BianchiDirector4× since May 26, 2026: 8,150 shares, avg. $78.18$637,151Sep 10, 2026
  • SaleBrooke StoryDirector2× since Nov 18, 2025: 2,550 shares, avg. $78.73$200,751Sep 4, 2026
  • SaleAhmet TezelChief Innovation Officer2,675 shares at $77.74$207,955Aug 11, 2026

Plus 11 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 77/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+10.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.2%
Start year 2020 (pandemic). Over 10 years: +16.9% a year
Revenue growth 33 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−15.8% (2019) → 10.3% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+15.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+6.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +12.5% a year for the price and +4.4% for the forecasts.
Forecast 2026 (sales)+9.7%
Forecast 2027 (sales)+7.1%
Projected 2028 (sales)+6.5%
Projected 2029 (sales)+5.8%
Projected 2030 (sales)+5.2%

LIVN screens overvalued: fair value 20% below the price. Compare with Abbott Laboratories, →

Earlier news

News mood ⓘNews mood, the average tone of recent news (99 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.
Note from the team Oct 18, 2026
AI conclusion: Double-digit growth in cardiopulmonary and epilepsy segments supports raised revenue and EPS guidance, while negative returns and net losses remain the central profitability weakness.
Main risk: Elevated spending on capacity and technology risks weakening cash conversion and pressuring free cash flow in the medical device operations.
LivaNova raised its full-year 2026 revenue and adjusted EPS guidance after double-digit growth in cardiopulmonary and epilepsy segments in the second quarter. Higher spending on capacity and technology at the same time prompted a cut to the free cash flow target. Will stronger sales and margins more than cover the extra investment, or will cash conversion remain the bigger challenge ahead of third-quarter results?
Join the discussion →

Compare LivaNova PLC with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 320 stocks

Beats the industry median on 6/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 53 · Above median
Fair Value upside −19.8% · Above median
Profitability
Return on equity (12 months) 15.5% · Top 25%
Return on assets −9.3% · Below median
Net margin (12 months) 13.0% · Above median
Operating margin (12 months) 7.2% · Below median
Growth and dividend
Revenue growth (quarter YoY) 9.9% · Above median
Balance sheet
Debt / equity 0.29× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/E (12 months) 25.8× · Pricier than median
P/B 4.22× · Priciest 25%
P/S (12 months) 3.36× · Pricier than median
Price / free cash flow (fiscal year) 29.3× · Pricier than median
EV/EBITDA 20.8× · Pricier than median
PEG 0.93× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)7 · sector 6
FUTURE (revenue growth)50 · sector 35
PAST (return on equity)62 · sector 17
HEALTH (low debt)86 · sector 98
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $325.87 $358.46 +10% vs LIVN
Boston Scientific Corporation BSX $42.75 $47.03 +10% vs LIVN
DexCom, Inc DXCM $79.41 $87.35 +10% vs LIVN
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.15 ¥197.22 +7% vs LIVN
GE HealthCare Technologies Inc GEHC $82.38 $69.92 −15% vs LIVN
Edwards Lifesciences Corporation EW $102.14 $81.94 −20% vs LIVN
Siemens Healthineers AG SHL €44.66 €34.95 −22% vs LIVN
Abbott Laboratories, ABT $109.93 $75.28 −32% vs LIVN
Medtronic plc MDT $101.80 $65.61 −36% vs LIVN
Koninklijke Philips N.V PHIA €27.33 €15.23 −44% vs LIVN

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

LivaNova PLC: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "LivaNova PLC Fair Value". https://www.fairvalue-calculator.com/stock/LIVN

Frequently asked questions

Is LivaNova PLC (LIVN) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of $72.21 versus a price of $89.99, about 20% lower (overvalued).
What is the fair value of LIVN?
Our model-based fair value for LivaNova PLC is $72.21 (as of Nov 5, 2026), built from audited fundamentals. The current price: $89.99.
What is the quality score of LIVN?
LivaNova PLC has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for LivaNova PLC (LIVN)?
Our model-based price target is the fair value of $72.21 (as of Nov 5, 2026) from 13 valuation models. Cautious scenario $42.84, optimistic scenario $110.18. It is a calculation from audited fundamentals, not an analyst target.
What is the LivaNova PLC stock forecast for 2026?
Our models put fair value at $72.21, about 20% lower versus a price of $89.99 (overvalued). Cautious scenario $42.84, optimistic scenario $110.18. The calculation is refreshed regularly with new filings.
What is the revenue of LivaNova PLC (LIVN)?
LivaNova PLC reported trailing-twelve-month revenue of about $1.5B (latest available figure, as of Nov 5, 2026).
What growth is priced into LivaNova PLC (LIVN)?
For today's price to be fair in a discounted-cash-flow model, LivaNova PLC would have to grow free cash flow by +15.2 % per year for five years (discount rate 9.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +8.2 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of LIVN use?
Our models discount LivaNova PLC at 9.5 %: a base by market capitalisation (mid), damped by beta 0.92, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For LivaNova PLC that is +15.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.5 %) and the same formula as our fair value.
How much growth has LivaNova PLC (LIVN) delivered so far?
Over the past 5 years revenue at LivaNova PLC grew +8.2 % a year. The price currently implies free-cash-flow growth of +15.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of LivaNova PLC (LIVN) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into LivaNova PLC (+15.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of LivaNova PLC (LIVN)?
The free-cash-flow yield on the price is 3.42 %: that much free cash flow LivaNova PLC produces per unit of market value. When it exceeds the discount rate of our models (9.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of LivaNova PLC (LIVN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For LivaNova PLC it is $72.21 per share (as of Nov 5, 2026), against a price of $89.99. It is the blended result of 13 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit).
Is LivaNova PLC stock overvalued or undervalued in 2026?
As of Nov 5, 2026, LIVN trades above its calculated fair value: price $89.99, fair value $72.21, a gap of about −20% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LIVN?
No. The price is what the market pays today ($89.99); the fair value is what the company's own numbers justify ($72.21). For LivaNova PLC the two are $17.78 per share apart. That gap is exactly why we show both numbers side by side.
How much is LivaNova PLC worth?
The market values LivaNova PLC at about $5.1B (market capitalisation, as of Nov 5, 2026). Per share that is $89.99; our models calculate a fair value of $72.21 per share.
What do the bullish and bearish scenarios say about LIVN?
Our models span a range for LivaNova PLC: cautious scenario $42.84, base $72.21, optimistic $110.18 per share (as of Nov 5, 2026, price $89.99). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of LIVN?
LivaNova PLC trades at a price-to-earnings ratio of 25.8 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $72.21 is built from several models across several years. Other multiples: PEG 0.9, P/B 4.2, P/S 3.4, EV/EBITDA 20.8.
What is the PEG ratio of LIVN?
The PEG ratio of LivaNova PLC is 0.93 (P/E divided by earnings growth, as of Nov 5, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of LivaNova PLC (LIVN)?
Balance-sheet figures for LivaNova PLC (as of Nov 5, 2026): return on equity 15.5%, debt of 0.29 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is LIVN from its 52-week high?
LivaNova PLC trades at $89.99, about 4% below its 52-week high of $94.19 and 82% above the low of $49.57 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $72.21 is for.
Which stocks are comparable to LivaNova PLC?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is LivaNova PLC stock attractive at the current price?
The data as of Nov 5, 2026: price $89.99, calculated fair value $72.21 (−20%), Quality Score 53/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LIVN calculated?
We run LivaNova PLC through 13 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of $72.21 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. LivaNova PLC itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of LivaNova PLC (LIVN)?
The closing price on Nov 6, 2026 was $89.99. Our model-based fair value is $72.21, about 20% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with LivaNova PLC right now?
Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($42.84 to $110.18) leaves room in how you read the outcome.

Key figures of LivaNova PLC

How large is the market capitalisation of LivaNova PLC (LIVN)?
The market capitalisation of LivaNova PLC is $5.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of LivaNova PLC (LIVN)?
The price-to-sales ratio of LivaNova PLC is 3.36 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of LivaNova PLC (LIVN)?
Earnings per share at LivaNova PLC are $3.49 (price ÷ EPS = P/E 25.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of LivaNova PLC (LIVN)?
The net margin of LivaNova PLC is 13.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of LivaNova PLC (LIVN)?
The return on equity (ROE) of LivaNova PLC is 15.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of LivaNova PLC (LIVN)?
On an EBIT basis the return on assets of LivaNova PLC is 1.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of LivaNova PLC (LIVN)?
The operating margin of LivaNova PLC is 7.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at LivaNova PLC (LIVN)?
Revenue at LivaNova PLC is growing +9.9% versus a year earlier (3y avg +10.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at LivaNova PLC (LIVN)?
Earnings per share at LivaNova PLC are growing −77.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does LivaNova PLC (LIVN) hold?
LivaNova PLC holds more cash than debt, $162M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch LivaNova PLC in the live analysis

One click puts LivaNova PLC on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.